Follow
About John
John McCamant was named editor of the Medical Technology Stock Letter in August 2000. He has spent 35 years on the front lines of biotechnology investing as an equities analyst and in venture capital. His expertise in biotechnology investments is a subject of media interest, and he is frequently consulted and quoted by The Washington Post, BusinessWeek, Reuters, and Bloomberg.
John's Articles
The Federal Trade Commission (FTC) recently cleared Amgen’s (AMGN) $28.7 billion buyout of Horizon Therapeutics after initially raising drug-bundling concerns. This clears the path for Amgen to close on its acquisition, one of the latest in a string of mergers and acquisitions in the pharmaceutical and “MedTech” space. That warrants exploring the future of SS Innovations International (SSII) and whether it could wind up in someone’s crosshairs, writes John McCamant, special to MoneyShow.
Esperion (ESPR) continues to showcase their positive CLEAR data with two oral presentations at the European Society of Cardiology (ESC) 2023 Congress, notes John McCamant, editor of The Medical Technology Stock Letter.
Alkermes (ALKS) recently reported their financials and reiterated fiscal year 2023 guidance which was updated in mid-June, when the company announced the final award from arbitration with Johnson & Johnson (JNJ), recalls John McCamant, biotech expert and editor of The Medical Technology Stock Letter.
Industry analysts estimate that robots account for 2% of surgical procedures worldwide. In the general surgery realm, approximately 10% of procedures in the US leverage robotics, compared to less than 1% outside the country. In other words, there is certainly significant room for further growth in the market, writes John McCamant, special to MoneyShow.
John's Videos
Biotech M&A results in overnight premiums of 50-200%. Find out how MTSL has discovered these biotech winners for our subscribers.
With hundreds of biotech companies to invest in, stock selection is paramount. In this session John will highlight past biotech winners to help frame current biotech recommendations.
John McCamant has spent 35 years on the front lines of biotech investing as an equities analyst and in venture capital. He has also edited the Medical Technology Stock Letter since the year 2000. In this session, he'll tell you about the methodology he uses to sift through hundreds of biotech companies to find the best in class drugs like MDGL for long-term growth. Plus, John will highlight the most attractive biotech opportunities in this premier growth sector for the rest of 2023 and beyond.
John McCamant, editor of the Medical Technology Stock Letter, says he expects a bidding war for MYOV and important catalysts from MDGL, TCRT, and PGEN in Q4.
Newsletter Contributions
Medical Technology Stock Letter
The Medical Technology Stock Letter (“MTSL“) is published 24 times per year and offers unique perspectives on medical trends, portfolio companies and focus on diversification and risk management strategies to help investors profit from today’s market volatility.
Learn More